<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Of the 167 countries modelled, between 0 and 48 countries (0–29% of countries, depending on programme coverage ranging from 70 to 90%) could achieve an 80% reduction in incidence using testing and treatment alone (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Appendix E—Table S7). The median relative reduction in hepatitis C incidence in the optimal strategies without a vaccine was 55% (inter-quartile range [IQR] 46–70%) (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Appendix E—Table S7 and Fig. 
 <xref rid="Fig3" ref-type="fig">3</xref>, top). With a 75% efficacious vaccine, between 15 and 113 countries (9–68%) could achieve the 80% incidence reduction target (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Appendix E—Table S7, Figs. 
 <xref rid="Fig2" ref-type="fig">2</xref> and 
 <xref rid="Fig4" ref-type="fig">4</xref>). The median relative reduction in incidence in the optimal strategies with a vaccine available was 81% (IQR 73–86%) (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Appendix E—Table S7 and Fig. 
 <xref rid="Fig3" ref-type="fig">3</xref>, bottom). 
</p>
